HOWEVER I'd be surprised if the FDA approved such a novel endpoint in cancer.
It is possible in the context of a separate companion trial with survival endpoint. With that said, it is certainly not in the time frame EXEL laid out. This type of SPA will require at minimum several iterations.
Market Data 
Markets 
AI
